Streetbeat News

Products Services

BIIB

LLY

Biogen shares are trading lower after the FDA approved Eli Lilly's Kisunla for early symptomatic Alzheimer's disease. Pharma stocks also fell after President Biden and Senator Sanders urged companies to lower drug prices.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 6:02 pm

IREN

Iris Energy Limited (NASDAQ:IREN) has secured $413 million to expand its Bitcoin mining operations, increasing its mining capacity to 30 EH/s and data center capacity to 510 MW. The company is also exploring asset sales, colocation agreements, and joint ventures to monetize its power and land portfolio. Iris Energy is committed to 100% renewable energy and has diversified into AI cloud services.

Portfolio Pulse from Murtuza Merchant

July 02, 2024 | 6:01 pm

NVS

A federal judge in Mississippi upheld a state law requiring drugmakers to provide discounts on medications dispensed by third-party pharmacies contracting with hospitals and clinics serving low-income populations. The ruling denied preliminary injunctions filed by PhRMA and Novartis AG (NYSE:NVS), who argued the law conflicted with federal regulations. Novartis plans to appeal the decision.

Portfolio Pulse from Vandana Singh

July 02, 2024 | 5:48 pm

AAPL

AMZN

GOOGL

META

MSFT

NVDA

TSLA

The article discusses the dominance of the 'Magnificent 7' technology companies—Microsoft, NVIDIA, Apple, Alphabet, Amazon, Meta Platforms, and Tesla—in the current market, comparing them to the 'Nifty Fifty' stocks of the 1970s. It questions whether these companies will maintain their dominance in the future, emphasizing the need for continued earnings growth and adaptation to new technologies.

Portfolio Pulse from Hayden Buckfire

July 02, 2024 | 5:46 pm

MARA

RIOT

Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) shares are pulling back after a rise on Monday, driven by Bitcoin's bounce from recent lows. Bitcoin's recent performance and ETF inflows are influencing these mining stocks.

Portfolio Pulse from Adam Eckert

July 02, 2024 | 5:44 pm

LLY

Eli Lilly's new Alzheimer's drug, Kisunla, will be priced at $32,000 for the first year, $12,522 for a 6-month course, and $695.65 per vial. This pricing strategy could impact the company's revenue and stock performance.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 5:39 pm

DAL

UP

Wheels Up Experience Inc (NYSE:UP) shares are surging due to a new streamlined product portfolio in partnership with Delta Air Lines Inc (NYSE:DAL). The new model offers greater flexibility, guaranteed availability, and rewards for frequent flyers, including Diamond Medallion Status with Delta.

Portfolio Pulse from Adam Eckert

July 02, 2024 | 5:38 pm

MRK

MRNA

MYNZ

mRNA technology is making significant strides in cancer treatment, with Moderna and Merck collaborating on an experimental mRNA vaccine combined with Keytruda showing promising results in melanoma treatment. Mainz Biomed is also advancing early cancer diagnostics with its ColoAlert test, showing high sensitivity in detecting colorectal cancer and precancerous lesions.

Portfolio Pulse from Upwallstreet

July 02, 2024 | 5:38 pm

LLY

SAVA

The FDA has approved Kisunla for early symptomatic Alzheimer's disease. A Phase 3 study showed that Kisunla slowed cognitive and functional decline by up to 35% and reduced the risk of disease progression by up to 39%. Once-monthly infusions reduced amyloid plaques by 84% on average, with nearly half of participants completing treatment in 12 months.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 5:36 pm

AXP

BAC

C

COIN

CRBG

HOOD

MS

PYPL

V

WFC

The article highlights significant options activity in the Financials sector, focusing on trades involving companies like PYPL, CRBG, MS, C, COIN, WFC, HOOD, V, BAC, and AXP. These trades, tracked by Benzinga's options activity scanner, indicate varying sentiments and potential trading opportunities.

Portfolio Pulse from Benzinga Insights

July 02, 2024 | 5:35 pm